Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBPI) mutation and loss in renal-cell carcinoma development

Genes Chromosomes and Cancer

Volumn 26, Issue 1, 1999, Pages 20-28

  Clifford, Steven C ^a   Walsh, Sally ^a   Hewson, Katie ^a   Green, Elaine K ^a   Brinke, Astrid ^b   Green, Peter M ^b   Gianelli, Francesco ^b   Eng, Charis ^c,d   Maher, Eamonn R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; DNA SEQUENCE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCATION; GENE LOSS; GENE MUTATION; GENE ORDER; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETIC RISK; HETEROZYGOSITY LOSS; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

PYRONIA TITHONUS;

EID: 0032819302     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.0.CO;2-6     Document Type: Article

References (38)

1. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
2. Brinke A, Green PM, Gianelli F. 1997. Characterization of the gene (YBP1) and transcript for the von Hippel-Lindau binding protein and isolation of the highly conserved murine homologue. Genomics 45:105-112.
3. Clifford SC, Prowse AH, Affara NA, Buys CHCM. Maher ER. 1998. Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumorigenesis. Genes Chromosomes Cancer 22:200-209.
4. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman, MI, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER. 1994. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303-1308.
5. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linchan WM, Klausner RD. 1995. Inhibition of transcription elongation by the VHL tumor-suppressor protein. Science 269:1402-1406.
6. Fearon ER. 1997. Human cancer syndromes: clues to the origin and nature of cancer. Science 278:1043-1050.
7. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM, Maher ER. 1994. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173.
8. Gailani MR, Stahlebackdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash DE, Bale AE, Toftgard R. 1996. The role of the human homolog of Drosophila patched in sporadic basal-cell carcinomas. Nat Genet 14:78-1.
9. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. 1995. E-cadherm expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195-5199.
10. Herman JG, Latif F, Weng YK, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB. 1994. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinomas. Proc Natl Acad Sci USA 91:9700-9704.
11. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JPJ, Markowitz S, Willson JKV, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD. Vogelstein B, Kunkel TA, Baylin SB. 1998. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95-6870-6875.
12. Ichimura K, Schmidt EE, Miyakawa A, Goike HM, Collins VP. 1998. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22:9-15.
13. Ioannou PA, de Jong PJ. 1996. Construction of bacterial artificial chromosome libraries using the modified P1 (PAC) system. In Dracopoli, et al., editors. Current protocols in human genetics, unit 5.15. New York: John Wiley and Sons.
14. Kibel A, Iliopoulos O, Decaprio JA, Kaelin WG. 1995. Binding of the von Hippel-Lindau tumor-suppressor protein to Elongin-B and Elongin-C. Science 269:1444-1446.
15. Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock LM. 1996. Cul-1 is required for cell-cycle exit in C.elegans and identifies a novel gene family. Cell 85:829-839.
16. Kon H, Sonoda Y, Kumabe T. Yoshimoto T, Sekiya T, Murakami Y. 1998. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene 16:257-263.
17. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. 1997. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC(-/-) colon carcinoma. Science 275:1784-1787.
18. Levy AP, Levy NS, Goldberg MA. 1996. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271:25492-25497.
19. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG. 1998. Regulation of hypoxia mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongin B/C and Cul2. Mol. Cell. Biol. 18:732-741.
20. Maher ER, Kaelin WG. 1997. von Hippel-Lindau disease. Medicine 76:381-391.
21. Mashal RD, Sklar J. 1996. Practical methods of mutation detection. Curr Op Genet Devel 6:275-280.
22. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 1995. 5' CpG island methylation is associated with transcriptional silencing of the tumor-suppressor P16/Cdkn2/Mts1 in human cancers. Nat Med 1:686-692.
23. Morin PJ, Sparks AB, Korinek Y, Barker N, Clevers H, Yogelstein B, Kinzler KW. 1997. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790.
24. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. 1989. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Nad Acad Sci USA 86:2766-2770.
25. Pause A, Lee S, Worrel RA, Chen DYT, Burgess WH, Linehan WM, Klausner RD. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94:2156-2161.
26. Pause A, Lee S, Lonergan KM, Klausner RD. 1998. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 95:993-998.
27. Sanchez Y, Lovell M, Marin MC, Wong PE, Wolfledbetter ME, McDonnell TJ, Killary AM. 1996. Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. Proc Natl Acad Sci USA 93:2551-2556.
28. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang ZP, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJM, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
29. Schwerdtle RF, Storkel S, Neuhaus C, Brauch H, Weidt E, Brenner W, Hohenfellner R, Huber C, Decker HJ. 1996. Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma. Cancer Res 56:2927-2930.
30. Shapiro MB, Senapathy P. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucl Acids Res 15:7155-7175.
31. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. 1998. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58:1130-1134.
32. Teh BT, Giraud S, Sari NE, Hii SI, Bergerat JP, Larsson C. Limacher JM Nicol D. 1997. Familial non-VHL non-papillary clear-cell renal cancer. Lancet 349:848-849.
33. Thoenes W, Storkel S, Rumpelt HJ. 1986. Histopathology and classification of renal-cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Path Res Prac 181:125-143.
34. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA. 1996. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 56:2263-2267.
35. Tsuchiya H, Iseda T, Hino O. 1996. Identification of a novel protein (VBP1) binding to the von Hippel-Lindau tumor suppressor gene product. Cancer Res 56:2881-2885.
36. Voesten AMJ, Bijleveld EH, Westerveld A, Hulsebos TJM. 1997. Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer 20:167-172.
37. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G. 1997. Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 57:2581-2585.
38. Xie JW, Murone M, Luoh SM, Ryan A, Gu QM, Zhang CH. Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal A, Epstein EH, de Sauvage FJ. 1998. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391:90-92.